EGFR Positive UK shared a post on X:
”Interesting discussion re future of osimertinib following the MARIPOSA study, which ‘shows a significant improvement in progression-free survival with amivantamab plus lazertinib in EGFR-mutant lung cancer, potentially setting a new standard of care.”
Source: EGFR Positive UK/X